|
252 documents found matching dt:memo*.
|
|
of 26
Prev
Next
|
|
|
|
Showing 1-10 of 252 documents
|
1.
Bulletin for Vioxx: Action Required - ""Project A&A XXceleration"": Patient Efficacy Assessment Kit (PEAK)
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
No. COX 01-023
Apr 20, 2001
Bulletin for VIOXXe
ACTION REQUIREO--prolect A & A XXeeleratlon: Patient Etflcacy Assessment Kit (PEAK)
Tg:
All Office Based Representatives whh Responsibility for VIOXX Action Required
A & A Specialty Representatives Action Required
All Hospital Representatives Action Required
All National Account Execupves and Customer Managers Background Information
(All Segments) '
PURPOSE:
To provide you with additional direction to help you effectively implement the new sample
initiative: PaUent gfficacy A_ssessment l9t. This kit will help you expand the use of VIOXX and
move share upward by enhancing your focus on your top A & A Prescribers for Project A & A
XXceleration. .
OVERVIEW:
Action Reeuired
You wi0 receive your PEAK program kits and additional stock botties through
two separate shipments. Please add a stock bottle of VIOXX to each of the
PEAK program kits upon receipt
You ara to use only materials provided by West Point for this program
Do not to create any materials such as tracki
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/akb00a10
|
|
| |
2.
Selected Physician Titration Analysis
|
Document Date:
|
19950725
|
|
Author:
|
Rizzo, Jackie
|
|
Corporate Author:
|
Parke-Davis
|
|
Search Terms in Context:
|
pgNbr=1
CONFIDENTIAL
pVIS
Peopie Who care
To.
F r fl
J. Rizzo
Memorandum
7/26195
Selected Physician T11trat5on Analysis f%^ =+ 1r...
L Illdch/E. Guemaro/J. Knoop 1 .2 q (995
cnBA GUERRERO
I-,
P-:1 \~ i UAL
-There was 38% increas the number of Prescriptions written in May by the 418
doctors, when o February prescriptions written by the same group of
physicians. ( The aggregated average milligrams per day was calculated based on the
number of prescriptions written by the 418 physicians in February (1573 Rx's) and May
(2166 Rx's)).
-A 096 increase i e average milligrams per day written by the 418 physicians was
also n comparing February to May, as follows:
Feb. avg. mlUigrams per day- 1369 mgs.
May avg. rn grams per day- 1611 rugs. io ~
On the following page is the hails dose breakdown among the physicians for both
February and May, as well as from the November 94 and July 94 analysis. Please
keep in mind that the 2/95 and 5/95 data includes all the same doctors while the 7/94
and 11/94
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/beb00a10
|
|
| |
3.
Neurontim Plus Plan
|
Document Date:
|
19960318
|
|
Author:
|
Guerrero, E
|
|
Corporate Author:
|
Parke-Davis
|
|
Search Terms in Context:
|
pgNbr=1
l~.+r:- .c-~O to O3 rrc .: ii wrr..._r. ...., r.c ar..
lot) PARKE-DAVIS
People Who Care
To: J. Knoop
From: E. Guerrero
Subject: Neurontin Plus Plan
Date: March 18, 19%
cc: L. Periow
THE PLAN
MEMO
ZkWZ~tion: A 3-month double-blind parallel group, multicenter study to determine
the efficacy and safety of Neurontin in newly diagnosed patients with partial epilepsy.
Protocol synopsis is attached-
biective: To Rather support monothe apy indication and help with the launch of
Neurontin to the primary care audience.
Judtma: Community Neurologists
rnn&W 2Q96 - 2Q98
2. Neurontin SamvleProgram
3.
Descrirrion: Sample Mail program
Objective: To increase Neurontin share of voice and help blunt the launch of
Topamax & La-*nictal
Audience: 10,000 Neurontin prescribers
2Q96 - 3Q96
p9I"MM-AisiNv")Ili-i1=+tM-;
bre To support Neurontin treatment algorithm
Audience: 4,000 Community Neurologists in dea7es 6-8
ire: 2Q96 - 3Q96
- 1 - I W 003959
pgNbr=2
I..'-ee - .= -7o io. M= .-.-... Z. =r.
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/bfa00a10
|
|
| |
4.
Bulletin for Vioxx: ""Project Power Play"" Teleconferences
|
Document Date:
|
20030400/e
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
No. COX 03-026
Apr 04, 2003
Bulletin for VIOXXs:
"Proiect PowerPlad" Teleconferences
To:
Office Based Representatives with Responsibility for VIOXX Action Required
Puraose: .. ... . . .. . . . .
To inform you of national teieconferences that will begin Tuesday, April 15. These teleconferences will
review Project Power Play for VIOXX,
Action Reauired:
Please make time on your calendar to dial into one of the below teleconferences
Pfease.folfow these steps to dial in and joinn your teleconference:- .. . Dial in a couple of minutes prior to conference start time Provide your name and Region-District-Territory (R-D-T) number to the operator
Your line will be placed on hold with music until conference start
Tuesday, Aprit 15, 2003
(TELECONFERENCE
TIME
NAME
Project Power Play 1 8:00 AM EST
Project Power Play
t00 CDT/6: 00 MDT/5:OOPDT.
Y 0.'00 CDT1g:00 MDTl8:OOPD
11:00 AM EST
Wednesday, April 16, 2003
CALL-tN DETAILS
Toll Free Numbe
Passcode
PRIVA
Toll Free Number:
Passcode:
PRIVA
RIVACY- ~
PRIVACY-
~
TELE
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/bkb00a10
|
|
| |
5.
4Q97 Goals
|
Document Date:
|
19971006
|
|
Author:
|
Saltel, Doug
|
|
Corporate Author:
|
Parke-Davis
|
|
Search Terms in Context:
|
T*,~~
13, ,
pgNbr=1
i
FARM-DAM -
i
Memorandum
ewer
Memo To: John Knoop
From: Doug Saltel
Subject: 4Q97 Goals
Copies
John,
Date: October 6, 1997
P - iReview these and see me if you if you have any questions
.?u-4 ice. it l y. M. S.L
or if you wo to dtscuss~fiis any er.
Update training modules for Dilantin, Neurontin, Cerebyx and ensure that rep updating/expanded
training takes place by year end.
2.
Neurontin - Dilantin Sales Presentation
3.
:Ipn;..: ,+7X-a [~i~i~r i- c1 i~i[0. ~-~:-N1<: tee':. fiv__ :.ls :~ 1 ,- .:±T: ,' w:.a:
5. '1 R.-Wr .
6. ed by the end of '97 with sales material ready
for Jan. production and distribution.
7. Finalize revised Neurontin sales materials for Jan. '98 launch, including utilization of Neon, STEPS,
etc. If we can launch this data earlier, let's discuss.
8. Pediatric- sNDAAted fv ke; ntin by year end.
Regards,
'w aocu T dng%4g9s jots Coop W., roemomo
V069786
1
pgNbr=2
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/cfa00a10
|
|
| |
6.
Bulletin for Vioxx: Action Required: REVISED Response to the New York Times Article
|
Document Date:
|
20010524
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
No. COX 01-031
May 24, 2001
Bulletin for VIOXX®:
Action Required: REVISED Response to New York Times Article
TO:
All Field Representations with Responsibility for VIOXX Action Required
All Hospital Representatives Action Required
A & A Specialty Representatives Action Required
A & A HSAs Action Required
Urology Representatives Action Required
Neurology Representatives Action Required
Managed Care NAEs and Customer Managers Background Information
(all segments)
DO NOT !NlTIATE DISCUSSIONS ON THE RESULTS OF THE V/OXXI GI OUTCOMES
RESEARCH (VlGOR) STUDY, OR ANY OF THE RECENT ARTICLES IN THE PRESS ON
VlOXX. YOU MAYRESPOND TO CUSTOMER INQUIRIES ONLY AS OUTLINED BELOW.
PURPOSE:
To provide you with important background information, obstacle responses and faxable
PIR instructions in the event that you are questioned by customers about the CV effects
of VIOXX.
ACTIONS REQUIRED:
Obstacle Response tf;S8: /odglnalN Issued In Bultotin COX 00-0291
'Doctor, there are no head-to-head studies comparing the cardiovascular prof
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/ckb00a10
|
|
| |
7.
Grant-Associates in Medical Marketing
|
Document Date:
|
19971107
|
|
Author:
|
Aquino, Mary Lou
|
|
Corporate Author:
|
Warner Lambert|Parke-Davis
|
|
Search Terms in Context:
|
CONFIDENTIAL
PARKEDA-VIS
Memorandum
Memo To: Kathy Accinni Date: 7/11/97
From: Mary Lou Aquino
Subject. GRANT-ASSOCIATES IN MEDICAL MARKETING
Copies .
Kathy:
Could you please process the following grant to Associates in Medical Marketing Co. Inc. This is an
addendum to a grant already sent to them.
To: Associates in Medical Marketing Co. Inc.
Total Amount: 550,088
Contact: Hilary Noden, Manager Financial Services
Telephone: 215-860-9600
Fax: 215-860-9558
Project Number: 704284
I've reopened Project No. 704284. Also, I kind of sort of told Hilary Noden that she would receive
the contracthbefore the end of this week. Is that possible? Oh, you can do it-I know you can!
Thanks.
Y 018570
pgNbr=1
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/dgb00a10
|
|
| |
8.
Educational Grants
|
Document Date:
|
19961014
|
|
Author:
|
Norman, Ian G
|
|
Corporate Author:
|
Parke-Davis Company
|
|
Search Terms in Context:
|
CONFIDENTIAL
1
PARKE-DAVIS
People Who Care
To: Kathy Accinni
From: Ian G. Norman
Subject: Educational Grants
Date: October 14, 1996
Dear Kathy,
Please process the enclosed Educational Grants:
MEMO
$adiden Amount Budget
Institute of Professional Education - LSU MCF 510,000 604366
Vanderbilt Department of Neurology $1,000 603174
Memphis Acedemy of Neurology $1,500 603174
Jim is in the process of creating 604 numbers, which can replace the 603 numbers above if necessary.
Please contact me if you require the 604 number. My aspen is 88115.
I'm
Thanks for your assistance. If you have any questions, please call.
i
Y 020785
pgNbr=1
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/ffb00a10
|
|
| |
9.
Neurontin Third Quarter Goals - 1997
|
Document Date:
|
19971006
|
|
Author:
|
Crook, Allen
|
|
Search Terms in Context:
|
Memo To: John Knoop
From: Allen Crook
Subject: NEURONTIN THIRD QUARTER GOALS - 1997
NEURONTIN GOALS
Third Quarter Goals
Date: 6/10/97
1. Complete analysis of Neurontin monotherapy indication potential supported by qualitative and
quantitative data. (July)
2. Based on potential in monotherapy market, solidify a marketing strategy and tactical proposal to meet
specified objectives. (July)
3. Coordinate with product planning the International Epilepsy Congress details to ensure the appropriate
forum for the -77 results dissemination. (July)
4. Solicit feedback from CBUs regarding a coordinated monotherapy launch. (July-Aug)
5. Complete promotional direct mail campaign to neurologists. (Aug)
6. Initiate situational analysis data collection and format sequence. (July-Aug)
7. Complete Vis-aid development and testing. (Aug)
8. Conduct "Emerging Applications"analysis and recommendations. (July)
9. Finalize monotherapy launch plan. (July)
10. Conduct 3Q toolbox meeting w/CBU's. (July)
11. Hold monthly dise
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/gfa00a10
|
|
| |
10.
Neurontin Goals
|
Document Date:
|
19970321
|
|
Author:
|
Crook, Allen
|
|
Corporate Author:
|
Parke-Davis
|
|
Search Terms in Context:
|
t
wARAER
canes
PAR E-DAVIS
Memo To: John Knoop
From: Allen Crook
Subject: NEURONTIN GOALS
Copies:
NEURONTIN GOALS
First Quarter Progress
Memorandum
Date: March 21, 1997
1. Held Merrit-Putnam Speakers Bureau Meetings. Monotherapy data was presented by Ahmad
Beydown, M.D. Additionally, Neurontin promotional strategy during first six months of 1997 was
communicated to over 115 faculty.
2. Vis-Aid development was completed, printed, and distributed to all TMs detailing Neurontin.
3. Held Southern Clinical Symposium at which 200 physicians participated. A variety of Epilepsy topics
were presented at a satellite symposium and will appear as a monograph during the 3rd Quarter in
conjunctionwith Monotherapy indication.
4. The psychiatry care initiative was planned, but was not approved by CME and legal. Alternative plans
are currently being developed.
5. Convention panels of selling message were developed. Worked with conventions department to ensure
consistent implementation at each show.
6. Developed a
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/jfa00a10
|
|
| |
|
Prev
Next
|
